Treatment of multiple sclerosis (MS)

摘要

A method for treatment of multiple sclerosis (MS) with Campath-1H with significant efficacy and a favorable safety profile is described, which offers an acceptable benefit/risk ratio. Especially described is the use of Campath-1H (alemtuzumab) for the production of a medicament for the treatment of multiple sclerosis (MS), comprising a first treatment cycle followed by at least one further treatment cycle of Campath-1H (alemtuzumab), in which each treatment cycle comprises 1-5 daily doses which are applied on consecutive days, wherein the daily dose is >0 and ≦12 mg, and wherein each treatment cycle is separated from the next cycle by at least 1-24 months. Also described are treatment regimens comprising the administration of less than 12 mg/day of Campath-1H for a period of 1-5 consecutive days.

主权项

1. A method of treating multiple sclerosis (MS) in a patient with a single MS immunotherapeutic consisting of an anti-CD52 antibody, the method comprising:
administering the anti-CD52 antibody to the patient at 1-12 mg/day for 1-5 days in an initial treatment cycle, and at least 3 months after the initial treatment cycle, administering the anti-CD52 antibody to the patient at 1-12 mg/day for 1-5 days in a second treatment cycle.